Patent License Agreement

PATENT LICENSE AGREEMENT

Before you use this: Complete Exhibits A–C, select one grant and a payment method, and confirm each patent's ownership, country, status, and existing rights. A pending application is identified separately from an issued patent. This agreement conveys only rights the Licensor actually controls.

This Patent License Agreement (the Agreement) is effective [__/__/____] between [LICENSOR LEGAL NAME], a [ENTITY TYPE AND JURISDICTION] at [NOTICE ADDRESS] (Licensor), and [LICENSEE LEGAL NAME], a [ENTITY TYPE AND JURISDICTION] at [NOTICE ADDRESS] (Licensee). Each is a Party.

1. Identified rights and scope

1.1 Licensed Patents. The Licensed Patents are only the issued patents and identified applications in Exhibit A, in the listed countries. A later patent or application enters Exhibit A only by a signed amendment. Continuations, foreign counterparts, reissues, extensions, and improvements are excluded unless identified in that amendment. The Parties will record patent status and any co-owner or third-party consent in Exhibit A before signing.

1.2 Grant. Licensor grants Licensee, during the Term and subject to this Agreement, the selected right under the Licensed Patents to perform only the checked activities in the Field and Territory in Exhibit B. Select one grant:

☐ Exclusive: Licensor will neither practice nor license another person within that Field and Territory, except for reserved rights expressly stated in Exhibit B.

☐ Sole: Licensor may practice within that Field and Territory but will not license another person there, except as stated in Exhibit B.

☐ Nonexclusive: Licensor may practice and license others within that Field and Territory.

Permitted activities (check all that apply): ☐ make ☐ have made by identified contractors ☐ use ☐ offer to sell ☐ sell ☐ import ☐ practice identified methods. Contractors may act only for Licensee and under written scope and confidentiality restrictions. The grant does not transfer title, imply a license to unlisted patents or other intellectual property, or promise that any activity is lawful in every country. An application listed in Exhibit A is included only to the extent a licensable interest exists; no issued-patent coverage is assumed before issuance.

1.3 Reserved rights. Licensor reserves [SPECIFY RESEARCH, GOVERNMENT, PRIOR LICENSE, CO-OWNER, OR OTHER RIGHTS OR WRITE NONE]. The Parties will identify separately any needed know-how, software, data, trademarks, regulatory permissions, or third-party technology; none is included by this patent grant.

2. Sublicenses

Select one: ☐ No sublicensing without Licensor's prior written consent. ☐ Sublicensing permitted only to [ELIGIBLE RECIPIENTS] for [PERMITTED ACTIVITIES] in the Field and Territory. ☐ Sublicensing permitted subject to [OTHER TERMS].

Every permitted sublicense must be in writing, remain within this Agreement's scope, prohibit further sublicensing unless expressly permitted here, and require records adequate for Section 3. Licensee remains responsible to Licensor for its sublicensee's performance. Within [NUMBER] days after execution Licensee will provide [COPY / MATERIAL TERMS] to Licensor, subject to agreed confidentiality limits. On this Agreement's end, existing sublicenses [END / CONTINUE ON SIGNED DIRECT-LICENSE TERMS IN EXHIBIT B]; no automatic assumption by Licensor is implied.

3. Consideration and records

Select each applicable payment type and complete its amount, due date, and currency in Exhibit C: ☐ upfront fee ☐ annual minimum ☐ running royalty ☐ per-unit royalty ☐ milestone payment ☐ sublicense consideration share ☐ other [DESCRIBE]. A blank or unchecked payment type is not owed.

Net Sales means amounts actually invoiced for covered transactions by Licensee and its permitted sublicensees to unrelated customers, less only documented deductions selected in Exhibit C, with no double counting for internal transfers. Exhibit C identifies the relevant product, method, component, or service; the patent and country basis for each royalty; exchange-rate method; refunds; bundled offerings; and treatment after a patent expires, is invalidated, or is abandoned. No royalty is presumed on unlisted inventions or jurisdictions.

Licensee will report [MONTHLY / QUARTERLY / OTHER] within [NUMBER] days after each period and pay in [CURRENCY] by [METHOD]. Reports will show units, gross receipts, selected deductions, royalty base, rate, sublicense receipts, credits, and balance, by country and product or patent category where applicable. Licensee will retain underlying records for [NUMBER] years. Licensor may audit relevant records [FREQUENCY] on [NUMBER] days' notice through an independent reviewer bound by confidentiality. Underpayment, audit costs, overpayment credit, late interest, and tax withholding are as selected in Exhibit C and subject to applicable law.

4. Development and diligence

Development milestones and dates, if any, appear in Exhibit C. Licensee will provide a progress report every [PERIOD] covering completed work, obstacles, and next steps. A missed milestone gives Licensor only the remedy selected in Exhibit C after [NOTICE PERIOD] notice and [CURE PERIOD] opportunity to cure, subject to stated extensions. If no milestone and remedy are selected, this section creates no automatic conversion or termination right.

5. Patent administration, improvements, and marking

5.1 Prosecution and maintenance. [PARTY] controls filing, prosecution, and maintenance decisions for each Exhibit A right, after consulting [OTHER PARTY] on material decisions affecting the licensed scope. Costs are borne [ALLOCATION]. Before an intentional abandonment or missed maintenance payment, the controlling Party will give [NUMBER] days' practicable notice and offer [SPECIFY ASSUMPTION OR OTHER RESPONSE], subject to owner, inventor, government, and patent-office requirements. Neither Party represents that an application will issue or a patent will remain valid.

5.2 Improvements. Each Party owns inventions created by its personnel except as a separate signed invention assignment states. Joint work and prosecution arrangements require a separate signed schedule identifying inventors, ownership, costs, license rights, and filing control. No future invention enters Exhibit A by implication.

5.3 Marking. For an applicable patented article, Licensee will use the marking method and current patent number or public patent-address information agreed in Exhibit B, where factually accurate and feasible, and retain marking records. The Parties will assess 35 U.S.C. § 287(a) for the actual product and claim; this Agreement does not guarantee damages for an unmarked article or authorize a false patent notice.

6. Federal funding and existing obligations

Exhibit A identifies any federal funding agreement, government license, domestic-manufacturing commitment, co-owner, university policy, security interest, prior license, or required consent known after the Parties' diligence. Where 35 U.S.C. § 202(c)(4) applies, the federal agency retains the stated paid-up license. Where § 204 applies to an exclusive U.S. use-or-sale grant for a subject invention, the Parties will attach the required domestic-manufacturing agreement or an actual agency waiver before that grant is used. Neither provision is assumed to cover every Exhibit A asset. Licensor will deliver supporting records listed in Exhibit A; unresolved limits are [STATE LIMITS OR CONDITION TO EFFECTIVENESS].

7. Infringement and third-party claims

Each Party will promptly give the other written notice of a material suspected infringement or challenge it learns of, with available evidence. [PARTY] controls investigation, counsel, settlement, and enforcement decisions, subject to [CONSULTATION/CONSENT TERMS]. The other Party will reasonably cooperate at [COST ALLOCATION]. Any lawsuit depends on actual ownership, standing, forum, claim, and procedural law; this Agreement alone does not assure either Party standing or recovery. A settlement may not impose an obligation on the other Party or impair its retained rights without written consent. Net proceeds after agreed documented costs are allocated [ALLOCATION].

8. Statements and risk allocation

Licensor states that, as of signing and subject to the exceptions disclosed in Exhibit A, it has authority to grant the rights it grants. Licensee states that it has authority to sign and will perform within the selected scope. Each Party will disclose known pending ownership or validity disputes in Exhibit A. Additional patent validity, noninfringement, commercialization, regulatory, and financial warranties are [SPECIFY OR WRITE NONE]; silence is not a factual warranty.

Third-party defense, indemnity, control of counsel, settlement consent, exclusions, and liability limits are [INSERT NEGOTIATED TERMS OR WRITE NONE]. A Party seeking a damages exclusion or cap must state its amount, covered claims, exceptions, and governing-law analysis in a signed addendum. Neither Party is promised an injunction, automatic fees, or a particular remedy by this Agreement.

9. Term, breach, and wind-down

The Term begins on the Effective Date and ends [DATE / LAST LISTED PATENT EXPIRY / OTHER DEFINED EVENT], unless validly ended earlier. A material breach may be cured within [NUMBER] days after written notice describing the breach; if uncured, the nonbreaching Party may terminate by further written notice, subject to applicable law. Licensee may end for convenience on [NUMBER] days' notice [IF AGREED]. The Parties will not treat insolvency, a bankruptcy filing, or a trustee appointment alone as automatic termination; 11 U.S.C. § 365(e) and, where applicable, § 365(n) govern bankruptcy effects.

At an effective end, Licensee will stop newly exercising the ended patent rights, provide a final report and pay accrued amounts within [NUMBER] days. Existing inventory may be sold only if a [NUMBER]-day sell-off is selected and within the selected scope, with ordinary reporting and royalties. Sublicense survival follows Section 2. Confidentiality, accrued payments, records and audit for pre-end periods, and dispute terms survive for [SPECIFY PERIOD OR EVENT]. No provision transfers ownership merely because the license ends.

10. Transfer, notices, and disputes

Neither Party may assign this Agreement without the other's written consent, except [SPECIFY PERMITTED SUCCESSOR TRANSACTION AND CONDITIONS]; a transfer of patent title or an exclusive grant must be assessed separately under 35 U.S.C. § 261 and other applicable law. This Agreement is governed by [STATE/COUNTRY] law, subject to applicable patent and bankruptcy law. Disputes will be heard in [IDENTIFIED COURT AND PLACE / SIGNED ARBITRATION ADDENDUM].

Notices must be sent to the addresses above by [DELIVERY METHOD] and take effect [RECEIPT RULE]. A Party may change its notice address by notice under this section. This Agreement and its signed exhibits are the entire agreement on this grant. Amendments and waivers require a writing signed by both Parties. An invalid provision is severed only to the extent required by applicable law. Counterparts and electronic signatures may be used where permitted by applicable law.

Signatures

Exhibit A — Patent and rights register

Condition to effectiveness or unresolved title/consent item: [DETAILS OR NONE].

Exhibit B — Grant selections and operational limits

Field of Use: [PRECISE FIELD]. Territory: [COUNTRIES IN WHICH EXHIBIT A RIGHTS EXIST]. Licensed products, methods, or services: [DESCRIPTION]. Exclusions and reserved rights: [DETAILS OR NONE]. Approved contractors: [NAMES OR CRITERIA]. Sublicense survival/direct-license terms, if selected: [TERMS OR NONE]. Marking plan and source of current patent numbers: [DETAILS OR NOT APPLICABLE].

Exhibit C — Economics and milestones

Net Sales deductions: [LIST OR NONE]. Bundles and internal transfers: [METHOD]. Currency conversion: [SOURCE AND DATE]. Expiry, invalidity, abandonment, and country-specific royalty treatment: [TERMS]. Withholding, late interest, audit discrepancy threshold, overpayment, and audit costs: [TERMS]. Development milestones, extensions, cure, and selected remedy: [TERMS OR NONE].